Evaluating anti-EGFR therapy effectiveness in specific colorectal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy of anti-EGFR therapy in patients with left-sided RAS-wild type metastatic colorectal cancer. Participants will be randomized into two main cohorts: a control group receiving standard chemotherapy with anti-EGFR therapy and an experimental group undergoing extensive molecular profiling to tailor treatment based on genetic variations. The study aims to assess how these different approaches impact treatment outcomes and patient responses. A total of 355 patients will be enrolled, focusing on those who have not previously received systemic therapy for metastatic disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Informed consent signed before commencing any procedures related to the clinical trial.
2. Age ≥18 years.
3. ECOG status 0-2.
4. Life expectancy greater than 12 weeks as assessed by the investigator.
5. Verified diagnosis of colorectal adenocarcinoma (C18.5, C19, C20).
6. Metastatic unresectable form of the disease that has not previously received any systemic therapy for the metastatic process (previous neo-/adjuvant therapy completed at least 6 months before the detection of metastases is allowed).
7. Left-sided localization of the primary tumor (from the splenic flexure of the colon inclusive).
8. Verified wild type KRAS, NRAS determined from tumor tissue.
9. Satisfactory function of hematopoiesis and internal organs:

   * absolute number of neutrophils ≥ 1.5×10 9 /l;
   * platelets ≥ 100×10 9 /l;
   * hemoglobin ≥ 90 g/l.
   * creatinine clearance above 50 ml/min;
   * total bilirubin \<1.5 X the upper limit of normal;
   * ALT or AST \>5 X the upper limit of normal in the presence of liver metastases or \>2.5 X the upper limit of normal in the absence of liver metastases.
10. Availability of a sufficient amount of tumor material for molecular genetic research. Tumor material must be collected no more than 24 months before inclusion in the study.

Exclusion Criteria:

1. Previous systemic therapy for metastatic disease.
2. Presence of KRAS/NRAS/V600E mutations (except for unknown BRAF status).
3. Uncertain KRAS/NRAS status
4. The presence of any other malignant tumor, with the exception of radically treated basal cell carcinoma, cervical cancer in situ, currently or within 5 years before inclusion in the study. Pregnant and lactating women, as well as planning pregnancy during the period of therapy in a clinical trial and 6 months after the end of therapy.
5. HIV infection, active hepatitis B, active hepatitis C.
6. Complicated primary tumor, requiring urgent surgical intervention. After it is eliminated, the patient can participate in the study.
7. The presence of a disease or condition that, in the opinion of the investigator, prevents the patient from participating in the study.
8. Impossibility of organizing central venous access.

Where it's running

• Moscow Multidiciplinary Clinical Center Kommunarka
  Moscow, Russia Recruiting
• N.N Blokhin Cancer Reserch Center
  Moscow, Russia Recruiting
• Reutov Clinical hospital
  Reutov, Russia Recruiting

Study contacts

• Study coordinator: Ilya Pokataev, phD
• Email: pokia@mail.ru
• Phone: +74955369406

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarkers in Colorectal Cancer: A Longitudinal Study Using Biobanks and Blood Samples

  This study tests whether clinical and molecular biomarkers from tumor tissue and blood can predict treatment response, recurrence, and survival in adults with colorectal cancer undergoing surgery.

  Recruiting at 2 sites Vorarlberg Institute for Vascular Investigation and Treatment · Bregenz, Vorarlberg and 3 other locations · NCT07913802

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer

  A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.

  Recruiting Masaryk Memorial Cancer Institute · Brno, Czech Republic · NCT07895459

• Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery

  Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07830576

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• AI-powered stool image analysis to see if it matches FIT results in colorectal cancer screening

  We’re testing whether AI-derived features from stool images can align with FIT results in adults being screened or evaluated for colorectal neoplasia.

  Recruiting Servicio de Salud Metropolitano Sur Oriente · Santiago, Santiago Metropolitan · NCT07740122

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.